代表委员通道｜罗晓东委员：为“云药”腾飞插上科技翅膀

Core Insights - Yunnan has a rich biodiversity and ranks among the top in China for traditional Chinese medicine cultivation area and variety, providing a solid foundation for the biopharmaceutical industry [1] - The biopharmaceutical industry in Yunnan has shown significant development, with companies like Yunnan Baiyao and Beitaini leading the market with their unique products [1] - Despite the potential, the industry faces challenges such as low levels of deep processing, insufficient core technological support, and a lack of integration between research and industry [1][2] Group 1: Industry Development - Yunnan's biopharmaceutical industry has made notable progress, with leading companies capitalizing on unique product offerings [1] - The industry is characterized by a strong foundation in traditional medicine, but it requires advancements in technology and processing capabilities [1] Group 2: Challenges and Recommendations - Key challenges include insufficient core technology, gaps in the translation of laboratory results to industry applications, and low levels of automation [1][2] - Recommendations include transitioning from resource-dependent to innovation-driven models, emphasizing technological empowerment in deep processing [1][2] - Establishing interdisciplinary innovation teams and enhancing collaboration between universities, research institutions, and enterprises is crucial for overcoming existing barriers [2] Group 3: Technological Advancements - The focus should be on modernizing traditional drugs and enhancing smart manufacturing through digital quality management systems and intelligent production lines [2] - The adoption of AI technology is recommended to optimize production parameters, reduce R&D cycles, and lower production costs [2] - Strengthening brand development and upgrading standards to promote the internationalization of natural drug products is essential for increasing the visibility of Yunnan's biopharmaceutical offerings [2]